Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs MG56 (Primary) ; MG56 (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Inmunotek
- 10 Mar 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 10 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.